S*BIO of Singapore Sells Cancer Drug Rights to MEI Pharma
S*BIO of Singapore has sold worldwide rights for a clinical stage oncology drug to MEI Pharma of San Diego. Pracinostat is an oral histone deacetylase (HDAC) inhibitor. The drug has completed Phase II clinical trials in patients with hematologic d..
Original Article: S*BIO of Singapore Sells Cancer Drug Rights to MEI PharmaNEXT ARTICLE